Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor–Mutated Non-Small Cell Lung Cancer Patients

BACKGROUND: Erlotinib is presently the first line treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) active mutation. An increasing number of evidences show that the treatment efficacy and toxicities are considerably heterogeneous among individuals. Hence,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Pharmacol
Prif Awduron: Liao, Dehua, Liu, Zhigang, Zhang, Yongchang, Liu, Ni, Yao, Dunwu, Cao, Lizhi, Chen, Yun, Fu, Yilan, Yang, Nong, Xiang, Daxiong
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2020
Pynciau:
Pharmacology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7225310/
https://ncbi.nlm.nih.gov/pubmed/32457635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00664
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg